

## **Luigi Battaglia**

### **Education**

Master Degree in Pharmacy (University of Turin, 2002)  
PhD in Drug Science (University of Turin, 2009)

### **Academic Positions**

2006-2012: Research Associate, Department of Drug Science and Technology, University of Turin  
2012-2017: Assistant Professor, Department of Drug Science and Technology, University of Turin  
2017-2020: Assistant Professor (Tenure Track), Department of Drug Science and Technology, University of Turin  
2020-: Associate Professor, Department of Drug Science and Technology, University of Turin

### **Research**

Full list of publications at <https://www.farmacia-dstf.unito.it/do/docenti.pl/Alias?luigi.battaglia#tab-pubblicazioni>

Research website: <https://www.farmacia-dstf.unito.it/do/docenti.pl/Alias?luigi.battaglia#tab-profilo>

Research keywords: solid lipid nanoparticles, nanoemulsions, drug delivery

### **Editorial Board membership**

Guest Editor of a thematic issue on Recent Patents in Drug Delivery and Formulation: Battaglia L, Gallarate M. New formulative strategies for lipid nano and microparticles preparation. Recent Pat Drug Deliv Formul. 2011 Sep;5(3):176-7. doi: 10.2174/18722111797200560. PMID: 21834775.

Editorial Board Member of Pharmaceutics

Congress Faculty Member: Focus on Cerebrospinal Fluid. From Basic to Clinical Research. Brescia 6<sup>th</sup> October 2017

### **Scientific Societies Membership**

Member of ADRITELF (Associazione Docenti e Ricercatori Italiani di Tecnologia e Legislazione Farmaceutiche)

Member of CRS (Controlled Release Society) Italian Chapter

Formerly Member of EASD (European Association for the Study of Diabetes)

### **Academic appointments**

Responsible for Erasmus+ Program agreement between the University of Turin and the University of the Basque Country

### **Most Recently financed projects**

Bando per il finanziamento di progetti di ricerca di Ateneo 2011: Compagnia di San Paolo: Sviluppo di nanoparticelle lipidiche solide (SLN) quali veicoli di farmaci antineoplastici per il miglioramento della terapia farmacologica del glioblastoma. ORTOWINST11 (Collaborator)

Contract (Ferbi s.r.l.): Inglobamento di anticorpi in particelle solide lipidiche a diversa composizione (SLN) (Collaborator)

Ricerca Locale 2016-2017: SLN per la veicolazione orale di insulina. (PI)

Fondazione CRT – 2018: FARMANET: Nuovi FARmaci per le Malattie NEurodegenerative” (Collaborator)

### **Ongoing projects**

Fondazione CRT – 2019: FarCoNano: Approcci Farmacologici Combinati e sistemi Nanotecnologici quali promettenti strategie per il trattamento del melanoma metastatico. € 35,000 (Collaborator)

Fondazione CRT – 2021: Nanocarriers lipidici nasali come device per la prevenzione e il trattamento di patologie cerebrovascolari (NanoLipid@NasalDevice). € 30,000 (PI)

Compagnia di San Paolo – ex post 2020: An Innovative Nanotechnology for Glioma Chemotherapy. € 54,605 (PI)

Contract (R Bio Transfer s.r.l.): Formulazione di nanoparticelle lipidiche solide per la veicolazione di farmaci chemioterapici, con particolare riguardo al trattamento dei tumori cerebrali (gliomi). € 38,454 (PI)